BAISHIDENG PUBLISHING GROUP INC
8226 Regency Drive, Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242 Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com http://www.wjgnet.com

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology
ESPS manuscript NO: 21276
Title: Boceprevir plus peginterferon/ribavirin for treatment of chronic hepatitis C in Russia
Reviewer's code: 01562153
Reviewer's country: Taiwan
Science editor: Jing Yu
Date sent for review: 2015-07-06 11:24
Date reviewed: 2015-07-14 15:30

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
[ ] Grade A: Excellent	[ ] Grade A: Priority publishing	Google Search:	[Y] Accept
[Y] Grade B: Very good	[Y] Grade B: Minor language polishing	[ ] The same title	[ ] High priority for publication
[ ] Grade C: Good	[ ] Grade C: A great deal of language polishing	[ ] Duplicate publication	[ ] Rejection
[ ] Grade D: Fair	[ ] Grade D: Rejected	[ ] Plagiarism	[ ] Minor revision
[ ] Grade E: Poor		[Y] No	[ ] Major revision
		BPG Search:	
		[ ] The same title	
		[ ] Duplicate publication	
		[ ] Plagiarism	
		[Y] No	

COMMENTS TO AUTHORS

In this manuscript, the authors aimed to evaluate the efficacy and safety of additional boceprevir (BOC) to peginterferon/ribavirin (PR) in Russian patients with chronic hepatitis C virus (HCV). Treatment-naive (TN) and treatment-experienced (TE) patients with chronic HCV genotype 1 infection were enrolled in this placebo-controlled, double-blind study. They found that the sustained virologic response (SVR) was 74.8% in the BOC plus PR arm compared with 46.2% in the control arm with a stratification-adjusted treatment difference of 29.2%, that the SVR rates were higher in the BOC arm in both TN and TE patients, and that anemia was increased in patients receiving BOC plus PR. This study was well designed and conducted. The authors obtained reasonable results. In addition, the manuscript was well prepared. Although the originality is not high, this article may provide useful information to the clinicians in managing patients with chronic HCV infection.

BAISHIDENG PUBLISHING GROUP INC
8226 Regency Drive, Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242 Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com http://www.wjgnet.com

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology
ESPS manuscript NO: 21276
Title: Boceprevir plus peginterferon/ribavirin for treatment of chronic hepatitis C in Russia
Reviewer's code: 02861252
Reviewer's country: Turkey
Science editor: Jing Yu
Date sent for review: 2015-07-06 11:24
Date reviewed: 2015-07-15 14:32

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
[ ] Grade A: Excellent	[Y] Grade A: Priority publishing	Google Search:	[Y] Accept
[ ] Grade B: Very good	[ ] Grade B: Minor language polishing	[ ] The same title	[ ] High priority for publication
[Y] Grade C: Good	[ ] Grade C: A great deal of language polishing	[ ] Duplicate publication	[ ] Rejection
[ ] Grade D: Fair	[ ] Grade D: Rejected	[ ] Plagiarism	[ ] Minor revision
[ ] Grade E: Poor		[Y] No	[ ] Major revision
		BPG Search:	
		[ ] The same title	
		[ ] Duplicate publication	
		[ ] Plagiarism	
		[Y] No	

COMMENTS TO AUTHORS

These results are very promising for Chinese patients...Good work..

BAISHIDENG PUBLISHING GROUP INC
8226 Regency Drive, Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242 Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com http://www.wjgnet.com

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology
ESPS manuscript NO: 21276
Title: Boceprevir plus peginterferon/ribavirin for treatment of chronic hepatitis C in Russia
Reviewer's code: 02995279
Reviewer's country: Italy
Science editor: Jing Yu
Date sent for review: 2015-07-06 11:24
Date reviewed: 2015-07-19 19:47

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
[Y] Grade A: Excellent	[Y] Grade A: Priority publishing	Google Search:	[Y] Accept
[ ] Grade B: Very good	[ ] Grade B: Minor language polishing	[ ] The same title	[ ] High priority for publication
[ ] Grade C: Good	[ ] Grade C: A great deal of language polishing	[ ] Duplicate publication	[ ] Rejection
[ ] Grade D: Fair	[ ] Grade D: Rejected	[ ] Plagiarism	[ ] Minor revision
[ ] Grade E: Poor		[Y] No	[ ] Major revision
		BPG Search:	
		[ ] The same title	
		[ ] Duplicate publication	
		[ ] Plagiarism	
		[Y] No	

COMMENTS TO AUTHORS

GENERAL COMMENTS 1. The study by Isakov and co-workers, that evaluated boceprevir-based triple therapy in patients with genotype 1 HCV infection, is characterized by a good overall quality. The overall result is remarkable because the success rate (overall result: 74.8% in the boceprevir plus PR arm compared with 46.2% in the control arm; results for the two patient subgroups: 78.4% vs 56.3% and 69.4% vs 30.0% in treatment-naive and treatment-experienced groups, respectively).) was higher than the values generally reported in the literature for the same regimen. On the basis of this trial, boceprevir has received regulatory approval in Russia. 2. In the Introduction, the authors describe the following regulatory scenario in Russia¨: "In Western countries, treatment of HCV infection has advanced dramatically over the last 5 years with the introduction of new targeted therapies that substantially shorten treatment duration and improve SVR rates[5,6]. However, in resource-constrained countries, standard treatment protocols are lacking, and PR dual therapy frequently remains the cornerstone of treatment[7,8]. " This sentence is adequate for the Introduction, but –in my view- this important point should be revisited and considerably expanded in the

Discussion.(see below) 3. In the Discussion, the issue of the current regulatory scenario in Russia is not dealt with . This is an important limitation of the present study for the following reasons: a) interferon-free regimens are now considered the current standard of care for these patients because of their undisputed effectiveness (close to 100% of success rates); in this context, the reasons why Russian patients can be treated with boceprevir-based triple therapy rather with the more recent regimens should be explained in much detail. 4. For example, the authors could provide the following information: current regulatory status of interferon-free regimens in Russia; expectations on when (and if) interferon-free regimens will receive regulatory approval in Russia; current cost of boceprevir and sofosbuvir expressed in the local currency and also converted into Euro and US dollars; general information on whether regulatory approval for any new drug implies, in Russia, a consequent reimbursement by the national health system; information on whether the treatments for HCV are already being reimbursed by the national health system or, alternatively, who is expected to pay for these treatments. SPEICIFC COMMENTS Table S1 is interesting and could be moved from the Supplementary Material into the main text (at least as regards the information concerning the SVR rate).